VivoSeq
Oncology

Urinary Tract Cancer

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Urinary Tract Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Active, not recruiting1 · 11%
Unknown status1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT02632409·709 enrolled
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Completed·ECOG-ACRIN Cancer Research Group·Phase 2·NCT02412670·36 enrolled
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00022191·608 enrolled
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Completed·—·Phase 2·NCT01191892·82 enrolled
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
Completed·TTulane University Health Sciences Center·Phase 2·NCT00028860
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002684·40 enrolled
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00021099·45 enrolled
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
Terminated·SWOG Cancer Research Network·Phase 2·NCT04871529·6 enrolled
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
Unknown status·—·Phase 2·NCT01118039·41 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)